SWedish Intensive Care Biobank (SWIC-B)

May 11, 2026 updated by: Michael Hultström, Uppsala University

Hereditary Influence on Risk Factors for Severe Illness in a Swedish Intensive Care Biobank

The goal of this observational study is to understand the genetic and molecular risk factors for developing critical illness in adult intensive care unit (ICU) patients in Sweden. The main questions it aims to answer are:

Which genetic variants are associated with increased risk of critical illness from conditions such as infections, sepsis, and organ failure?

Can circulating proteins and metabolites mediate the effect of genetic risk factors on the severity of illness?

Participants will:

Provide blood samples at ICU admission and again 3-6 months after discharge Consent to genetic analysis and data linkage with national health registries

Have their ICU treatment and outcomes followed using registry and clinical data

This study aims to build a national infrastructure for rapid sample collection and analysis that can also support research in future pandemics.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

25000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Any patient admitted to intensive care at a hospital in Sweden

Description

Inclusion Criteria:

  • Adults admitted to intensive care in Sweden

Exclusion Criteria:

  • Non adults
  • Not admitted to intensive care

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
ICU admission
Any patient admitted to ICU in Sweden

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
30 day mortality
Time Frame: 30 days
Death of any cause within 30 days of ICU admission
30 days
ICU admission
Time Frame: 30 days
ICU admission for any specific cause
30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Uppsala University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

December 30, 2035

Study Completion (Estimated)

December 30, 2035

Study Registration Dates

First Submitted

November 24, 2025

First Submitted That Met QC Criteria

May 11, 2026

First Posted (Actual)

May 13, 2026

Study Record Updates

Last Update Posted (Actual)

May 13, 2026

Last Update Submitted That Met QC Criteria

May 11, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SWIC-B
  • 2024-04531-01 (Other Identifier: Swedish Ethical Review Authority)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Swedish legal requirements preclude sharing individual patient data. Patient data access for collaborators is provided on a secure system.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Any Condition Underlying Critical Illness

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe